Pekka Kallunki

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial.

Journal: The Lancet. Neurology

Published: December 18, 2025

The Amplification of Alpha-Synuclein Amyloid Fibrils is Suppressed under Fully Quiescent Conditions.

The Amplification of Alpha-Synuclein Amyloid Fibrils is Suppressed under Fully Quiescent Conditions.

Journal: Angewandte Chemie (International ed. in English)

Published: October 04, 2024

New prospects for 89Zr-immuno-PET in brain applications - Alpha-synucleinopathies.

New prospects for 89Zr-immuno-PET in brain applications - Alpha-synucleinopathies.

Journal: Nuclear medicine and biology

Published: September 22, 2024

Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.

Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.

Journal: NPJ Parkinson's disease

Published: May 31, 2024

Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study.

Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study.

Journal: The Lancet. Neurology

Published: January 25, 2024

Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.

Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 13, 2023

Corrigendum to: DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.

Corrigendum to: DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.

Journal: Human molecular genetics

Published: September 21, 2020

A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission.

A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission.

Journal: Translational psychiatry

Published: April 04, 2017

Antibodies against the C-terminus of α-synuclein modulate its fibrillation.

Antibodies against the C-terminus of α-synuclein modulate its fibrillation.

Journal: Biophysical chemistry

Published: August 02, 2016

Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.

Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.

Journal: Journal of psychiatry & neuroscience : JPN

Published: July 09, 2016

Development of Passive Immunotherapies for Synucleinopathies.

Development of Passive Immunotherapies for Synucleinopathies.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: July 20, 2015

Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum.

Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum.

Journal: Neuroscience letters

Published: August 12, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026